DOTATATE PRRT for Neuroendocrine Tumors: South Australian Clinical Experience
South Australian experience with 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendocrine tumors provides real-world efficacy and safety data for this somatostatin-based treatment.
Quick Facts
What This Study Found
South Australian experience with 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendocrine tumors provides real-world efficacy and safety data for this somatostatin-based treatment.
Key Numbers
189 patients treated over 11 years (2011-2022). Assessed for toxicity, radiological response, quality of life, and survival.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide therapeutic knowledge.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to evidence?
- ?Next research?
Trust & Context
- Key Stat:
- Key finding South Australian experience with 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendoc
- Evidence Grade:
- Based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival.
- Published In:
- ESMO gastrointestinal oncology, 8, 100146 (2025)
- Authors:
- Altus, L M, Forster, J C, Mercurio, J, Kitchener, M, Corsini, N, Nenke, M, Price, T, Patel, D, Chew, R, Moffat, D, Unger, S, Cehic, G
- Database ID:
- RPEP-09913
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
South Australian experience with 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendocrine tumors provides real-world efficacy and safety data for this somatostatin-based treatment.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09913APA
Altus, L M; Forster, J C; Mercurio, J; Kitchener, M; Corsini, N; Nenke, M; Price, T; Patel, D; Chew, R; Moffat, D; Unger, S; Cehic, G. (2025). The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival.. ESMO gastrointestinal oncology, 8, 100146. https://doi.org/10.1016/j.esmogo.2025.100146
MLA
Altus, L M, et al. "The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival.." ESMO gastrointestinal oncology, 2025. https://doi.org/10.1016/j.esmogo.2025.100146
RethinkPeptides
RethinkPeptides Research Database. "The South Australian 177Lu-DOTATATE peptide receptor radionu..." RPEP-09913. Retrieved from https://rethinkpeptides.com/research/altus-2025-the-south-australian-177ludotatate
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.